You are here
Michelle Cochran, M.D., MD
Dr Cochran currently works as the medical director of the Nashville Center for Hope & Healing and the NeuroScience and TMS treatment centers; in addition she maintains a role as a private practice psychiatrist. The clinics have grown to two sites with two physicians, multiple nurse practitioners, therapists, and many support staff and technicians. Dr Cochran has experience treating a variety of psychiatric conditions, using a comprehensive approach with therapy, counseling, pharmacogenomic testing, medication, and neuromodulation. She received her undergraduate degree at Centre College, her medical training at University of Louisville School of Medicine, and she completed her postgraduate medical education at Vanderbilt University Medical Center in Nashville, Tennessee. During her psychiatry residency she was Chief Resident. Additionally, she completed the Management Program for Physicians and Senior Healthcare Administrators at Vanderbilt University, Owen School of Management. A current diplomat of the American Board of Psychiatry and Neurology (with active maintenance of certification), Dr. Cochran is a member of the Tennessee Psychiatric Association, Tennessee Medical Association, Nashville Academy of Medicine, Tennessee Women in Medicine, and Southern Psychiatric Association. Since her residency years, she has also been a member, Fellow (2011), and now Distinguished Fellow (2018) of the American Psychiatric Association. Dr. Cochran has been on the Clinical Faculty in the Department of Psychiatry at Vanderbilt University Medical Center since 1996 and has lectured to undergraduate, graduate, and postgraduate students as well as private practitioners. For over 15 years, she has been active on numerous advisory boards professionally and personally. Before retiring from inpatient psychiatric care and establishing her outpatient private practice, she was the medical director for many psychiatric units and programs in the Middle Tennessee area. Since 2011, Dr. Cochran has offered repetitive transcranial magnetic stimulation to her patients as an option for the treatment of Major Depressive Disorder. Dr. Cochran and her staff have trained extensively in the use of repetitive transcranial Magnetic Stimulation (rTMS) including training at Berenson Allen’s Non-Invasive Brain Institute, Duke University and other specific advanced device trainings. She has been active in the Clinical TMS Society (CTMSS) on many levels including serving on the executive committee as the VP-Elect (2016-2017), President (2017-2018), and with the Education and Annual meeting committees. Most recently she has been helping advance the PULSES introductory course with other active CTMSS board members.
Mahmoud S Okasha, DLFAPA
Dr. Okasha is the Medical Director of Comprehensive Psychiatric Care, a private practice located in Norwich Connecticut where he is also the Primary Investigator (P.I.) and has conducted over 70 clinical trials. He is an Associate Clinical Professor at the Department of Psychiatry at Yale School of Medicine.
David L Dunner, M.D., Md
Dr. Dunner is the Director of the Center for Anxiety and Depression, a private consulting psychiatric practice located in Mercer Island, WA, and is Professor Emeritus at the University of Washington in Seattle.
Dr. Dunner earned his AA at George Washington University in Washington, DC, and his MD at Washington University School of Medicine in St. Louis, Missouri. After graduating, he completed his internship at Philadelphia General Hospital in Philadelphia, Pennsylvania, and his residency in psychiatry at Washington University School of Medicine. He then spent two years at the NIMH and was involved in research studies of bipolar depression. Among these research studies was the development of the concept of bipolar spectrum disorders - particularly, Bipolar I and Bipolar II.
After NIMH, Dr. Dunner spent eight years at Columbia University (Assistant, then Associate Professor of Clinical Psychiatry) and at the New York State Psychiatric Institute. He worked for Dr. Ronald Fieve and published studies of clinical, biological, familial and outcome factors comparing unipolar and bipolar disorders. Among these research studies was the identification of rapid cycling as a major factor leading to poor treatment outcome with lithium.
From 1978 to 2006, Dr. Dunner was at the University of Washington (Professor in the Department of Psychiatry and Behavioral Sciences). He was Chief of Psychiatry at Harborview Medical Center and later the Director of the University of Washington Psychiatry Outpatient Center. He was Director of the Center for Anxiety and Depression while at the University and has moved the Center to his private location. He developed a clinical trials unit (PharmacoResearch) for the study of psychiatric disorders and collaborated with individuals from Psychology and Radiology as well as colleagues in the Department of Psychiatry and Behavioral Sciences. He has mentored several individuals who have progressed to established academic careers. He was actively involved as a teacher in the medical school and continues to teach in the psychiatry residency program and at continuing medical education events for practitioners.
Dr. Dunner is a member of several scientific organizations: American Psychiatric Association (Distinguished Life Fellow); The American College of Psychiatrists (Emeritus Fellow, former Member of the Board of Regents); American College of Neuropsychopharmacology (Fellow Emeritus); American Psychopathological Association (Fellow, former President); Psychiatric Research Society (former President); Society of Biological Psychiatry (former President); West Coast College of Biological Psychiatry (former President); and Collegium Internationale Neuropsychopharmacologicum (Fellow). Dr. Dunner serves on several editorial boards and was Editor-in-Chief of Comprehensive Psychiatry until the end of 2014 when he retired from that position.
Dr. Dunner’s research interests were primarily devoted to psychopharmacological and psychotherapeutic treatments for mood and anxiety disorders. He has authored or co-authored more than 360 articles and edited or co-edited more than 10 books. His clinical focus is on difficult to treat patients with depression and bipolar disorders. He is involved in the treatment of patients who have treatment-resistant mood disorders with various pharmacotherapies including augmentation strategies and repetitive transcranial magnetic stimulation (rTMS) and is a referral source for other treatments, such as ECT and VNS.
Linda L Carpenter, M.D., MD
Dr. Carpenter is a Professor of Psychiatry in the Alpert Medical School of Brown University and Chief of the Mood Disorders Program at Butler Hospital. Dr. Carpenter completed her undergraduate degree at the University of Michigan, her MD from the University of Pennsylvania, and internship in internal medicine, a residency program in psychiatry, and a clinical neuroscience research fellowship at Yale University. She joined the faculty at Brown in 1997 and has continued her path as a physician-scientist investigating the neurobiology of, and new treatments for, major depression and other mood and anxiety disorders. She led a 10-year, federally funded translational research program focusing on the development of laboratory biomarkers signaling risk for mood/anxiety disorders, and understanding the impact of early life stress on adult biology. She has also conducted a number of randomized clinical trials sponsored by industry and NIH, investigating investigational drugs and devices for treating depression, including Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS). She is the founding Director of the Butler Hospital TMS Clinic and Neuromodulation Research Facility where she treats patients with pharmacoresistant depression and works with a variety of Brown-based research faculty who incorporate noninvasive brain stimulation techniques into their clinical research. He current research projects involve using imaging and EEG biomarkers to optimize and individually customize TMS therapy for depression.
Ms. Westerfield attended Sanford Brown College for Medical Assisting, and completed the program in 2011. After working for a surgical practice, in 2013 she accepted the position of TMS Technician with TMS St. Louis, and helped to develop their TMS practice. She is now the TMS Coordinator, and manages a staff of 4 TMS Technicians for 3 devices as well as obtaining insurance authorizations and overseeing the day-to-day operations for the practice.
Richard A. Bermudes, M.D.
Dr. Bermudes is Board Certified in Adult Psychiatry and Family Medicine, with 20 years’ experience caring for patients. He founded TMS Health Solutions in 2007, serves as the practice’s Medical Director, and is an expert on TMS practice organization and policy development. With his background as a professor and researcher, he leads the practice in its mission to educate the public and clinicians on both mental health issues and TMS, to continually seek the most advanced treatments, and to actively contribute to the medical community’s knowledge of mental health conditions and therapy efficacy.
He recently wrote and edited “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice”, a book with key research findings on TMS as well as its potential to be used for other conditions such as OCD, PTSD, Adolescent Depression and mild dementia. He is experienced in treating patients with MDD (Major Depressive Disorder), including Unipolar Depression.
Dr. Bermudes is a caring, collaborative practitioner with a structured, goal-oriented approach to treating mental health conditions. His treatment plans may include TMS, medication management or cognitive therapy.
Jay D. Gunkelman, QEEG-D
Jay Gunkelman, QEEG Diplomate, has processed over 500,000 EEGs since 1972. He has served as president of The International Society for Neurofeedback and Research, as well as a board member and treasurer of the Association for Applied Psychophysiology and Biofeedback and is a past-president of the Biofeedback Society of California. Jay was the first EEG technologist to be certified in QEEG (1996) and was granted Diplomate status in 2002. He has conducted, published or participated in hundreds of research papers, articles, books and meetings internationally. He co-authored the textbook on EEG artifacting (2001). Jay remains busy with current projects and publications related to his seminal paper on EEG endophenotypes (2005, Clinical Electroencephalography). He is co-founder and Chief Science Officer of Brain Science International and is a popular lecturer worldwide on the topic of QEEG and phenotype identification of neurological disorders.
Todd Hutton, M.D., MD
Dr. Hutton began his TMS practice in 2009 when he founded his first Southern California TMS Center location in Pasadena, CA. Since then, Dr. Hutton has expanded SoCal TMS to 6 locations throughout the greater Los Angeles area. Dr. Hutton serves as the Clinical TMS Society Board of Directors and is Chairman of this year's Annual Meeting committee. A Fellow of the American Psychiatric Association, he is also an Associate Clinical Professor of Psychiatry at the USC Keck School of Medicine. Dr. Hutton received his Bachelors Degree in Biology in 1985, and his Doctor of Medicine in 1989 both from the University of California, Irvine. He completed his residency training in Psychiatry at Los Angeles County/USC Medical Center, where he spent his last year as Chief Resident.
John P O'Reardon, DFAPA
Dr. O’Reardon received his medical degree from University College Cork, in Ireland. He initially trained in primary care and is board certified in family medicine in Ireland and the UK. He completed his residency training in psychiatry at the University of Pennsylvania, and subsequently fellowships in psychopharmacology and in cognitive therapy. He was a Van Ameringen fellow at the Beck Institute for Cognitive Therapy and is a founding fellow of the Academy of Cognitive Therapy. Dr. O’Reardon is a Diplomate of the American Board of Psychiatry and Neurology. Dr. O’Reardon’s clinical and research interests include treatment resistant mood disorders, the development of novel neuromodulation therapies in psychiatry such as TMS, VNS, tDCS, and deep brain stimulation (DBS) along with cognitive therapy, and the night eating syndrome. He has served as an investigator in numerous clinical trials of therapeutic interventions including medications, cognitive therapy, TMS, VNS, DBS and tDCS. He was full time faculty at the University of Pennsylvania for 15 years, and attained Associate Professor rank there. He is currently in private practice. He has made many contributions to the literature in his areas of interest in leading specialty journals including the Archives of General Psychiatry, Biological Psychiatry, Journal of Clinical Psychiatry, and the American Journal of Psychiatry. Has more than 100 peer-reviewed scientific publications. He has been teaching faculty at the APA, Institute of Psychiatric Services and International Society for ECT and Neurostimulation (ISEN), Clinical Transcranial Magnetic Stimulation Society (CTMSS) annual meetings in the area of mood disorders and neuromodulation treatments.
Matias m Bonanni, M.D., M.ScDr. Bonanni is the Chief of the Neuromodulation Department at INAC using TMS in clinical and research settings (depression, bipolar disorder, schizophrenia, tinnitus, pain, addictions, ADHD, ASD). Dr. Bonanni graduated medical school from the Universidad del Salvador, Argentina with honors and completed his psychiatry residency training at Buenos Aires University. He was director of the Instituto de Neurociencias Aplicadas a la Clínica (INAC) in Argentina. First TMS center in Argentina (2006). He is also very involved in many medical society organizations.
Saxby A Pridmore, M.D.
Dr. Pridmore is a Professor of Psychiatry at the University of Tasmania, Australia. He brought the first TMS device to the southern hemisphere (Royal Hobart Hospital) and reported the normalization of the DST using TMS in 1999, and the first blind comparison of TMS and ECT in 2000 (widely ignored). Currently, attached to ‘TMS Tasmania’, a service of Saint Helen’s Private Hospital (Hobart).
Amit Etkin, M.D., Ph.D.
Dr. Etkin is an Associate Professor in the Department of Psychiatry and Behavioral Sciences at Stanford, a member of the Stanford Neurosciences Institute, and an Investigator at the Palo Alto VA. He has received multiple awards, most notably the NIH Director’s Pioneer Award in 2017, and is an editor at Neuropsychopharmacology. Dr. Etkin is trained as both as a neuroscientist and psychiatrist. The overarching aim of the Etkin lab is to understand the neural basis of emotional disorders and their treatment, and to leverage this knowledge to better understand how the brain works and to develop novel treatment interventions. In support of this goal, Dr. Etkin also collaborates with neuroscientists, engineers, psychologists, physicians and others to establish a new intellectual, scientific and clinical paradigm for understanding and manipulating human brain circuits in healthy individuals and for treating psychiatric disease.
Alvaro Pascual-Leone, M.D., Ph.D
Dr. Pascual-Leone is a Professor of Neurology and an Associate Dean for Clinical and Translational Research at Harvard Medical School. He serves as the Chief for the Division of Cognitive Neurology and the Director of the Berenson-Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center. Dr. Pascual-Leone is also one of the directors of the Football Players Health Study at Harvard University (https://footballplayershealth.harvard.edu).
Dr. Pascual-Leone works as a practicing cognitive neurologist at Beth Israel Deaconess Medical Center. His research aims at understanding the mechanisms that control brain plasticity across the lifespan to be able to modify them for the patient’s optimal behavioral outcome, prevent age-related cognitive decline, reduce the risk for dementia, and minimize the impact of neurodevelopmental disorders (www.brainfitclub.org).
Dr. Pascual-Leone’s research combines various brain imaging and brain stimulation methodologies to characterize brain plasticity and brain network dynamics across the lifespan in health and disease, to be able to modify them for an individual’s optimal behavioral outcome, preventing disability and restoring function in patients with neuropsychiatric diseases. He is considered a world leader in the field of noninvasive brain stimulation where my contributions span from technology development, through basic neurobiologic insights from animal studies and modeling approaches, to human proof-of-principle and multicenter clinical trials. Thompson Reuters has designated him a ‘most highly cited author’ and recognized him as one of 2015 World's Most Influential Scientific Minds, and one of the World’s top 15 Neuroscience Researchers. Dr. Pascual-Leone has authored more than 650 scientific papers (H-index 133; i10index 482) and several books, and is listed inventor in 17 patents.
Dr. Pascual-Leone is a dedicated mentor and teacher, recognized with a K24 NIH award and various distinctions, including Harvard’s Daniel Federman Outstanding Clinical Educator Award. He directs an intensive mini-fellowship in noninvasive brain stimulation (http://tmslab.org/education-intensive.php ), and the Sidney R. Baer, Jr. Foundation Fellowship in the Clinical Neurosciences (http://tmslab.org/education-baer-fellowship.php).
Dr. Pascual-Leone is the recipient of several international honors and awards and his work has wide general public appeal and outreach through dissemination in articles in the lay press, documentaries on television and radio, and several trade books (e.g. Norman Doidge, The Brain That Changes Itself; John E. Robison, Switched On).
Flavio Frohlich, Ph.D.
Dr. Frohlich received a degree in electrical engineering at the Swiss Federal Institute of Technology in Zurich, an International Diploma in electrical engineering at the Imperial College in London, and his PhD in computational neurobiology at UC San Diego. He did a postdoctoral fellowship at Yale University studying cortical network activity. Flavio’s goal is to revolutionize how we treat psychiatric illnesses. His vision is that understanding brain network activity will enable the development of novel non-invasive brain stimulation paradigms. Flavio is convinced that such rational design of neurotherapeutics will open the door for individualized, highly effective brain stimulation in psychiatry. Flavio is passionate about combining different methodological approaches to scientific problems and is a pioneer in the field of network neuroscience. His research integrates neurobiology, engineering, and medicine. The Frohlich Lab (1) performs computer modeling, (2) combines electrophysiology, imaging, brain stimulation, and behavioral assays in animal models, (3) records and modulates human brain activity, and (4) studies new treatments in randomized controlled clinical trials.
Martijn Arns, Ph.D.
Dr. Arns graduated in the late 90’s as a biological psychologist at Radboud University in Nijmegen. After several projects in the field of applied neuroscience in Sydney (Westmead Hospital), Munich (Max Planck Institute for Psychiatry) and Scotland (Organon Research in Newhouse), he began in 2001 with what is now known as Research Institute Brainclinics and Psychology Practice Brainclinics (now part of the neuroCare Group). Martijn received his PhD at Utrecht University on the topic of 'EEG-based personalized medicine for ADHD and depression' and is specialized in applying brain imaging techniques to determine the appropriate treatment for patients with ADHD and depression, also referred to as precision medicine or Research Domain Criteria (RDoC). He is specialized in the development and application of neuromodulation techniques such as neurofeedback in the treatment of ADHD, magnetic brain stimulation (rTMS) in the treatment of depression, sleep and chronobiological aspects of ADHD and Depression. Martijn supervises a team of researchers and PhD's at Research Institute Brainclinics and a team of psychologists and psychiatrists at the neuroCare Group, all specialized in these topics. At Research Institute Brainclinics Martijn carries out research into personalized medicine, RDoC, neuromodulation techniques, sleep and chronobiology in collaboration with various international researchers and universities. In addition, he teaches several (internationally) accredited training courses such as an ‘rTMS in Depression’ workshop and a ‘Neurofeedback in ADHD’ training course. Martijn is director and researcher at Research Institute Brainclinics and Chief Scientific Officer at the neuroCare Group in Munich.
Kevin M Kinback, M.D., md
Graduating from Loma Linda University Medical School in 1992, Dr. Kinback did psychiatry training at Loma Linda, was Chief Resident, and remains on the faculty as Assistant Clinical Professor of Psychiatry. He began private practice in Mission Viejo in 1995. With a keen interest in cutting-edge medicine, Advanced TMS was founded in 2009. Specializing in TMS therapy for treatment-resistant depression, Dr. Kinback has treated hundreds with TMS therapy.
Michael Kabar, M.D.
Dr. Kabar is a Peruvian-American physician who trained as a psychiatrist at the University of Maryland and the San Mateo County Residency Program in Palo Alto, California where he was chief resident. He is Board-Certified and worked in the San Francisco Bay Area for almost 20 years in private practice, at UC Berkeley and at other psychiatric facilities where he served as a medical director, including the Mission Multicultural Assertive Community Treatment Program, the first ACT program in Northern California. He has co-authored the book "Texto de Psiquiatria", the most important textbook of psychiatry in all of Latin America, edited by Dr. Renato Alarcon and published by the Panamerican Health Organization (PAHO). He is currently a professor at Peruvian University Cayetano Heredia (UPCH). He was initially trained on TMS by Dr. Marcolin at Hospital Das Clinicas of the University of Sao Paulo, Brazil. He returned to Peru in 2010 to start a TMS Center, the "Instituto de Neuroestimulacion de Lima" where he has treated more than 400 patients. He has given talks on TMS at the Latinamerican Psychiatric Association (APAL) and other regional meetings and at the Clinical TMS Society meeting in Atlanta. He has published articles on TMS in South American Journals and is a reviewer for the journal "Transcultural Psychiatry".
Jill M. Harkavy-Friedman, Ph.D.
Dr. Harkavy-Friedman leads the American Foundation for Suicide Prevention’s research grant program to advance the field of suicide prevention. With 30 years of experience as a clinician and a researcher, she is passionate about translating research into practice, publishing over 100 articles. She assists with AFSP’s development of programs and messages that reflect best practices and current research.
Harkavy-Friedman earned her B.A. in Psychology at the University of Pennsylvania and her PhD. in Clinical Psychology at the University of Florida. In 1984, she joined Montefiore Medical Center/Albert Einstein College of Medicine, establishing the Adolescent Depression and Suicide Program. In 1989, she moved to Columbia University/New York State Psychiatric Institute where she was an associate professor before joining AFSP. She maintains a clinical practice in Manhattan.
Tabitha Iseger obtained her Bachelors degree in Biology at Leiden University in 2011. Following, she obtained a Masters degree in Neuroscience in 2013 at VU University Amsterdam. During her Masters degree, she obtained work experience at King’s College London, working in the field of MRI. After her Masters, she started working at the Academic Medical Center in Amsterdam, in the field of MRI, depression/ADHD and pharmacology. She started her PhD in 2015 in the Netherlands at Brainclinics Research Institute in collaboration with Utrecht University. During her PhD she is focussing on depression, EEG, TMS and the heart-brain network. Currently, her main topic is NCG-TMS, a new method to target the depression network using heart rate.
William M. Sauve, MD
Dr. Sauvé is a Regional Medical Director for Greenbrook TMS NeuroHealth Centers, a dedicated center for the treatment of depression using Transcranial Magnetic Stimulation.
After receiving his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, Dr Sauvé completed his residency in adult psychiatry in the National Capital Consortium in Washington, DC, which includes the National Naval Medical Center in Bethesda, Walter Reed Army Medical Center in Washington, DC, and Malcolm Grow Medical Center at Andrews Air Force Base in Maryland. Shortly afterward, he was deployed to the Al Anbar Province, Iraq, as the regimental psychiatrist for the 7th Marine Regiment. After 11 years of active-duty service, he left the US Navy to become Military Clinical Director at Poplar Springs Hospital. Dr Sauvé is certified by the American Board of Psychiatry and Neurology, Inc.
Dr Sauvé recently coauthored “The Science of Transcranial Magnetic Stimulation” with Laurence Crowther for the July issue of Psychiatric Annals. He is a member of the American Psychiatric Association and a Faculty Member at the Neuroscience Education Institute.
Citiation: Sauvé, W. M. and L. J. Crowther (2014). "The Science of Transcranial Magnetic Stimulation." Psychiatric Annals 44(6): 279-283.
Alexander George Lyford-Pike, M.D.
Dr. Lyford-Pike is the Director of the Institute of Psychiatry and Psychology of Montevideo (IPM) and has been a TMS provider and researcher since 1999. He is also the former President of the Biological Psychiatry Society of Uruguay (SPBU), currently the honorary member of SPBU. In 1978 he received his medical degree from the Universidad de la República (UDELAR), Montevideo Uruguay and completed his psychiatrict training at UDELAR in 1981.
Mark Schlickman, M.D.
Dr. Schlickman received his undergraduate degree cum laude in biochemistry from Brandeis University. His initial interest in pediatrics transformed into psychiatry during medical school at the University of Massachusetts. He was chief resident of psychiatry at the University of Massachusetts Medical Center. His private group practice, APOGEE Integrated Mental Health Services, Inc. was founded in 1994.
His work in TMS is the culmination of over twenty years of psychiatric practice, which has included an eclectic mix of somatic and psychodynamic treatments. He provides individual and group psychotherapy, medication management, TMS, and has patients with VNS implants. He still uses his past as a fitness instructor to counsel patients in lifestyle medicine strategies.
Dr. Schlickman is board certified in psychiatry by the American Board of Psychiatry and Neurology. He is a diplomate of the American Group Psychotherapy Association, and facilitates three open-ended groups which focus on mood disorders, trauma, and disability. He has a teaching affiliation with the UMass/Memorial psychiatric residency training program as a lecturer in group therapy, and will start lecturing on TMS.
Paul E. Croarkin, D.O., MSc
Dr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents. This includes biomarker work to optimize diagnostic practices and the delivery of brain based interventions such as transcranial magnetic stimulation. A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. This research is funded by a variety of industry, federal, and foundation grants. Dr. Croarkin is an associate professor of psychiatry and the division chair for child and adolescent psychiatry for the Mayo Clinic Department of Psychiatry and Psychology. In 2017 he received a National Institute of Mental Health Biobehavioral Research Award for Innovative New Scientists (BRAINS) for ongoing work focused on optimizing transcranial magnetic stimulation for adolescent depression. He is the current vice president of the Clinical TMS Society and is an active member of the annual meeting and research committees.
Michelle N McDonnell, Ph.D.
Dr. McDonnell is a Neurological Physiotherapist and Neuroscientist. Her research investigates mechanisms to promote neuroplasticity following brain damage, and the use of non-invasive brain stimulation to further our understanding of functionally beneficial changes in the brain. She has a particular interest in the changes that occur in the brain in the first few weeks post-stroke, and whether this corresponds to a period of heightened neuroplasticity. Recent research has investigated the efficacy of interventions delivered in the first few weeks post-stroke to improve arm function, and how to improve delivery of evidence-based therapeutic interventions.
Daniel Press, M.M.Sc.
Dr. Press is the clinical director of the Berenson-Allen Center for Noninvasive Brain Stimulation and the medical director for the Cognitive Neurology Unit at Beth Israel Deaconess Medical Center (BIDMC). He is also an associate professor of neurology at Harvard Medical School (HMS).
Dr. Press earned his undergraduate degree from the University of Pennsylvania and his medical degree from the University of Connecticut School of Medicine. He received a scholarship to spend one year at the National Institutes of Health (NIH) through the Howard Hughes Medical Institute-NIH Research Scholars Program, where he pursued research in the Clinical Brain Disorders Branch of the National Institute of Mental Health. Dr. Press completed a neurology residency in the Harvard Longwood Neurology Training Program and a fellowship in cognitive neurology at BIDMC. He received a master of medical sciences degree from HMS through the Harvard-MIT Clinical Investigator Training Program.
Dr. Press is a leader in education, research, and clinical treatment, with a focus on diseases like Alzheimer’s disease and Parkinson’s disease. His research concentrates on studying the effects of brain disease on one’s ability to learn new motor skills, and how those effects can be reversed. In collaboration with motor control experts from the Harvard School of Engineering and Applied Sciences, Dr. Press has developed a model for how motor learning may be impaired in Alzheimer’s disease. Using this model, he has begun testing whether noninvasive brain stimulation to specific brain areas can treat this deficit.
In his role as clinical director for the Berenson-Allen Center, Dr. Press and his team treat patients with neuropsychiatric conditions, including medication-resistant depression. This team has performed over 10,000 transcranial magnetic stimulation (TMS) treatments to more than 200 patients in the last 10 years, helping them to achieve and maintain more normal lives. He also has directed a medical education course to help train others from around the world in the clinical aspects of non-invasive brain stimulation.
Dr. Press is a member of a number of medical societies and serves on medical advisory boards for both the Massachusetts Registry of Motor Vehicles and the Massachusetts branch of the Alzheimer’s Association. He has authored or co-authored more than 50 scientific articles, chapters, and reviews, and has written editorials for leading medical journals including Neurology and The New England Journal of Medicine.
Lauren Valencia, LCSW
Ms.Valencia, LCSW holds a B.S. in Psychology and Criminology from Florida State University and went on to receive her Master's of Science in Social Work from the University of Tennessee College Of Social Work in 2013. Since 2013 she has acted as a Therapist and TMS Coordinator for the Nashville Center for Hope & Healing (NCHH).
With NCHH Ms.Valencia sees a variety of clients for intake, individual, and couples therapy. In therapy, she utilizes CBT and a strengths-based approach. She works collaboratively with patients to establish goals and develop plans to progress toward those goals effectively. As TMS Coordinator Lauren meets with each TMS patient daily to maximize progress during their treatment course. Previously, she has worked with the Veteran's Health Administration and also in geriatrics, inpatient surgery, hospice, and addictions. Her diverse experiences enable her to discuss a variety of subject matter with the attention they deserve. She has previously spoken at the 2016 and 2017 Clinical TMS Society Annual Meetings.
Sherri Capone, CMA
Sherri Capone is a Certified Clinical Medical Assistant & the TMS Coordinator at Long Island neuroCare Therapy.
Stephanie Debnath, RN
Ms. Vergara has been doing TMS for 7 years and has treated hundreds of patients. She is currently the Senior TMS Technician at Southern California TMS Center and is in charge of all technician training and supervision at their 6 locations. She has been a Psychiatric Nurse for the last 10 years, and previously did ECT at Cedars-Sinai hospital. She is currently furthering her education to become a Nurse Practitioner.
Joshua Elan Kuluva, M.D.
Dr. Kuluva is a Board Certified psychiatrist and neurologist with a strong academic and research background, as well as experience with both Cognitive Behavioral Therapy and Psychodynamic Psychotherapy. He treats patients with clinical depression and neurologic disorders, and individuals with neurologic disorders who experience psychiatric symptoms such as geriatric patients with cognitive issues and depression or adults with developmental delays and behavior concerns. He also specializes in treating patients with traumatic brain injury and the post-concussive syndrome.
Dr. Kuluva is passionate about developing authentic and trusting relationships with his patients and seeking leading-edge therapies for treatment-resistant psychiatric and neurological conditions. In his treatment approach, he considers the physical, emotional, and social aspects of coping with an illness. He views the patient as a whole person rather than focusing on one issue without personal context. Dr. Kuluva strives to ensure that his patients are active participants in their healthcare. He provides the highest level of patient education and encourages patients to evaluate all treatment options so they select the treatment that feels most comfortable to them.
Roxane Kim Zotyka, M.D., Certified TMS Treater
Mrs. Zotyka is a veteran of the health care industry since 1982, she is a Certified TMS Technician and patient advocate. She coordinates new patient education, clinical evaluations, and case management for patients receiving TMS Therapy. Roxane has completed courses at Duke University in Transcranial Magnetic Stimulation and Harvard Medical School’s course in Transcranial Direct Current Stimulation. She has attended two American Psychiatric Association Annual Meetings (2013 and 2015) and the 1st International Brain Stimulation Conference in Singapore alongside Dr. Cress in March 2015. She also attended the UCLA Individualized Neuromodulation for Neurologic and Psychiatric Disease Conference in October 2015. Roxane is dedicated to expanding her knowledge in neuromodulation and ensuring that each patient receives full support and continuum of care and is a vital part of the journey at the TMS Serenity Center.
Eric Tirrell, TMS clinical operator / Neroumodulation Research Coordinator
Mr. Tirrell completed his undergraduate degree in psychology at the University of Rhode Island. He is the senior TMS clinical operator at Butler Hospital’s TMS Clinic and has been providing TMS services for depression for 3 years. He also serves as Research Coordinator for the Butler Neuromodulation Research Facility and played a key role in a conducting a Neuronetics' sponsored study of efficacy, EEG, and imaging biomarkers 5Hz TMS in adults with comorbid PTSD and MDD. Mr. Tirrell has extensive experience with all aspects of TMS clinical care, (including screening and selecting candidates; initiating treatments; managing side effects; daily clinical assessment of patients; documentation of procedures; monitoring progress with standardized depression measures; management of a TMS clinical outcomes database) as well as in integration of a Behavioral Activation psychotherapy protocol during routine TMS clinic visits. He is experienced operating Neurostar, Magstim, and investigational TMS device systems. Mr. Tirrell works with a number of Brown University-based faculty to incorporate noninvasive brain stimulation techniques into their clinical research, investigating potential effects on smoking cessation, working memory, executive functioning, exercise, OCD, and bipolar disorder. He has had extensive training in collection of physiological data (EEG, cardiac) for biomarker development and he is currently using MRI-neuronavigated procedures in a study to optimize TMS Therapy.
Sheldon E. Jordan, M.D.
Dr. Sheldon Jordan graduated from Brooklyn Tech in Industrial Design and completed premedical studies at Harvard University. He majored in art, psychology and natural sciences at Johns Hopkins and was mentored by one of the original leaders in American psychology, G Wilson Shaffer. His neurophysiology research was with David Olton, one of the pioneers in the brain mechanisms underlying memory and learning. Dr. Jordan has published original research in behavior modification of autistic and developmentally disabled children at the Kennedy Institute at Johns Hopkins Hospital and developed programs for schizophrenic and depressed patients at the Sheppard Pratt Institute.
Dr. Jordan was a Goldwyn Scholar and graduated from UCLA Medical School in 1977 with the Upjohn Award for best student in combined research and academics and the Gold Medal in Surgery. Medical Internship, Residency and Fellowships in clinical neurophysiology while staffing the electroencephalography laboratory and electromyography laboratory and completing all studies in 1981. He was also recognized as the best Resident teaching award with the Augustus Rose Award.
Today, Dr. Jordan is recognized as a top neurologist by Best Doctors in America, Who’s Who, Global Edition, and Super Doctors. His philosophy is to listen to patients tell their stories. He believes that each person must be treated as an individual. To him there is nothing more gratifying than getting someone better. He still thinks that there is a place for quality medicine and in his practice he seeks to provide the antidote to cookie cutter medicine.
Noah S. Philip, M.D.
Dr. Philip received his BSc from McGill University, and his MD from Albany Medical College where he graduated AOA and with a Distinction in the Study of Biomedical Ethics. He completed psychiatry residency training at the Alpert Medical of Brown University, followed by an NIH-sponsored T32 Fellowship, and then a Neuromodulation Fellowship at Butler Hospital.
Dr. Philip is an Associate Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the Director of Psychiatric Neuromodulation at the Providence VA Medical Center. He is affiliated with the Center for Neurorestoration and Neurotechnology at the Providence VA Medical Center, the Alpert Medical School of Brown University, and with Butler Hospital.
Dr. Philip’s lab uses cutting edge technology to understand and treat serious psychiatric disorders, such as major depressive disorder and posttraumatic stress disorder (PTSD). He uses noninvasive brain stimulation and functional neuroimaging towards these goals, with method that include transcranial magnetic stimulation (rTMS, sTMS, TBS, etc.), low-current stimulation (tDCS), network-based resting state functional connectivity and virtual reality. Dr. Philip's research was recently featured in the American Journal of Psychiatry, Biological Psychiatry and the National Neuroscience Curriculum Initiative.
Dr. Philip has received numerous awards and recognition, including election to Associate Membership of the American College of Neuropsychopharmacology in 2018. He was initially funded by a Career Development Award (CDA-2, Clinical Science R&D), and since that time has received funding for neuroimaging and brain stimulation studies from the VA (Rehab R&D), NIDA, Department of Defense, and through industry and small-business collaborations.
Dr. Philip also plays a significant training/teaching role at Brown, where he is a co-investigator on the NIMH R25-supported psychiatry resident research track, and regularly serves as a mentor locally and through national organizations such as the Society for Biological Psychiatry and Career Development Institute for Psychiatry.
Joseph Zohar, Ph.D.
Dr. Zohar is the Director of Psychiatry A and Director of the Anxiety and Obsessive Compulsive Clinic of this institute. He graduated from Tel Aviv University Sackler School of Medicine in 1973, trained in psychiatry at the University of Washington, Seattle and at the Jerusalem Mental Health Center, Israel, where he was the director of the Resistant Depression Unit. In 1984, Prof. Zohar joined the laboratory of Dr. Dennis Murphy at the National Institute of Mental Health, Bethesda, Maryland ,where he was acting director of the Obsessive-Compulsive Clinic. In 1986 he served as chairperson on the panel for Obsessive-Compulsive Disorder of the American Psychiatric Association Task Force on Treatments of Psychiatric Disorders in 1989 and as a member of the DSM-IV Obsessive Compulsive subcommittee. In 1992, Prof. Zohar established the International Council on Anxiety and OCD that is currently entitled World Council on Anxiety, and in 1993 he was nominated as the chairperson of the anxiety and OCD section of the World Psychiatric Association (WPA) along with his role as the chairperson of the World Council on Anxiety.In 1994 he was the chairperson of the 7th meeting of the European College of Neuropharmacology (ECNP) and in 1995 was elected as a member of the executive committee of this organization and as the chairperson of the Israel Society for Biological Psychiatry. In 1996 Prof. Zohar was nominated as a member of the WHO Expert Advisory Panel on Neuroscience. In 1997 he was elected to the executive committee of the World Federation of Societies of Biological Psychiatry. Prof. Zohar is the associate editor of the World Journal of Biological Psychiatry, the international editor of the journal CNS Spectrum and is also on the editorial boards of several journals, including European Psychiatry, International Journal of Psychiatry in Clinical Practice and Neuropsychobiology. He is the author of more than 100 scientific papers and has edited 11 books focusing on refractory depression, Obsessive-Compulsive Disorder, and PTSD. Prof. Zohar founded of the Israeli consortium on PTSD, is currently the commander of the chief installation of the Israeli Defense Force for treating PTSD, and he is serving as a special advisor to the Ministry of Defense in relation to PTSD.
Laura Schulze is a PhD candidate at the University Health Network.
Mr. Esuf completed his undergraduate degree at UC Davis, majoring in Biochemistry and Molecular Biology. Prior to working at TMS Health Solutions, he ran day-to-day operations at a non-profit student-run clinic, while serving as a Finance Coordinator and board member. Mr. Esuf began working at TMS Health Solutions as a TMS technician soon after graduation. He worked as a TMS technician for two years before becoming the Clinical Program Manager. He is currently the Sr. Manager of Quality and Training where his primary focus is on the delivery of quality initiatives for improved patient experience, hiring, training and team development.
Shawn McClintock, Ph.D., PhD, MSCS
Dr. McClintock is an Associate Professor in the Department of Psychiatry at UT Southwestern Medical Center and is Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Duke University School of Medicine. He received his Ph.D. in Clinical Psychology from UT Southwestern Medical Center (2006). In 2008, Dr. McClintock was appointed a NIH Clinical Scholar in the UT Southwestern Medical Center Department of Clinical Sciences where he received his M.S. in Clinical Sciences with Distinction (2011). He completed a National Institute of Mental Health T-32 Postdoctoral Fellowship in mood disorder research at UT Southwestern Medical Center and a postdoctoral fellowship in brain stimulation and neurotherapeutic modulation at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute.
Dr. McClintock is a globally recognized expert on the use of translational neurocognitive methods to develop new and safe neuromodulation interventions for the treatment of major depressive disorder. Such interventions include Electroconvulsive therapy (ECT), magnetic seizure therapy (MST), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS). Also, he is developing newer translational methods of neurocognitive assessment in order to elucidate similar and divergent cognitive processes across species, with the goal of identifying underlying cognitive component processes of neurocognitive sequelae in patients treated with neuromodulation interventions.
Albert Leung, M.D., Professor of Anesthesiology and Pain Medicine
Dr. Albert Leung is a Professor of Anesthesiology and Pain Medicine at the UC San Diego, School of Medicine. He is the Director, Center for Pain and Headache Research at the VA San Diego Healthcare System (VASDHS). He is the founder of the Anesthesia Pain Transcranial Magnetic Stimulation (TMS) treatment clinic at the VASDHS. Under his leadership, this rapidly growing clinical service provides TMS therapy for veterans with intractable chronic pain conditions such as mild traumatic brain injury (MTBI) related headaches and other co-morbid conditions. In recent years, his research group has completed several novel studies in validating the efficacy and mechanisms of rTMS in alleviating MTBI related headache and other service related chronic pain conditions with correlated functional imaging studies. He is at the forefront of promoting TMS as a treatment for pain.
Elyssa Sisko, BA, CCRC
Ms. Sisko is the clinical research coordinator for Advanced Mental Health Care in Palm Beach County, FL. She began working with Dr. Tendler as a research assistant and TMS technician after graduating with bachelor’s in biology from Rollins College. Ms. Sisko has extensive experience administering both rTMS (Magstim & Neurostar) and dTMS (H1, H4, H7, and H9 coils) as well as training others. Elyssa was an operator for the dTMS clinical trial for MDD which gained FDA approval. Additionally, she has experience treating TMS patients affected by Parkinson’s, stroke, multiple sclerosis, bipolar depression, bipolar mania, anxiety, panic, OCD, addiction, depression, PTSD, and chronic pain. Currently, Elyssa Sisko is the clinical research coordinator and rater for dTMS clinical trials for smoking cessation, OCD, PTSD, MDD and Bipolar depression.